Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography
2009; Wiley; Volume: 81; Issue: 1 Linguagem: Inglês
10.1111/j.1600-0404.1990.tb00926.x
ISSN1600-0404
AutoresJoakim Tedroff, Sten‐Magnus Aquilonius, A. Laihinen, U. K. Rinne, Per Hartvig, Jesper Andersson, Hans Lundqvist, Merja Haaparanta‐Solin, Olof Solin, Gunnar Antoni, Antony D. Gee, Johan Ulin, Bengt Långström,
Tópico(s)Neuroscience and Neuropharmacology Research
ResumoActa Neurologica ScandinavicaVolume 81, Issue 1 p. 24-30 Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography J. Tedroff, Corresponding Author J. Tedroff Department of Neurology, Uppsala University, SwedenJ. Tedroff, Department of Neurology, University Hospital, Uppsala, SwedenSearch for more papers by this authorS.-M. Aquilonius, S.-M. Aquilonius Department of Neurology, Uppsala University, SwedenSearch for more papers by this authorA. Laihinen, A. Laihinen Department of Neurology, University of Turku, FinlandSearch for more papers by this authorU. Rinne, U. Rinne Department of Neurology, University of Turku, FinlandSearch for more papers by this authorP. Hartvig, P. Hartvig Department of Hospital Pharmacy, University Hospital, Uppsala University, SwedenSearch for more papers by this authorJ. Andersson, J. Andersson Department of Radiation Sciences, Uppsala University, SwedenSearch for more papers by this authorH. Lundqvist, H. Lundqvist Department of Svedberg Laboratory, Uppsala University, SwedenSearch for more papers by this authorM. Haaparanta, M. Haaparanta Department of Medical Cyclotron Laboratory, University of Turku, FinlandSearch for more papers by this authorO. Solin, O. Solin Department of Medical Cyclotron Laboratory, University of Turku, FinlandSearch for more papers by this authorG. Antoni, G. Antoni Department of Organic Chemistry, Uppsala University, SwedenSearch for more papers by this authorA. D. Gee, A. D. Gee Department of Organic Chemistry, Uppsala University, SwedenSearch for more papers by this authorJ. Ulin, J. Ulin Department of Organic Chemistry, Uppsala University, SwedenSearch for more papers by this authorB. Långström, B. Långström Department of Organic Chemistry, Uppsala University, SwedenSearch for more papers by this author J. Tedroff, Corresponding Author J. Tedroff Department of Neurology, Uppsala University, SwedenJ. Tedroff, Department of Neurology, University Hospital, Uppsala, SwedenSearch for more papers by this authorS.-M. Aquilonius, S.-M. Aquilonius Department of Neurology, Uppsala University, SwedenSearch for more papers by this authorA. Laihinen, A. Laihinen Department of Neurology, University of Turku, FinlandSearch for more papers by this authorU. Rinne, U. Rinne Department of Neurology, University of Turku, FinlandSearch for more papers by this authorP. Hartvig, P. Hartvig Department of Hospital Pharmacy, University Hospital, Uppsala University, SwedenSearch for more papers by this authorJ. Andersson, J. Andersson Department of Radiation Sciences, Uppsala University, SwedenSearch for more papers by this authorH. Lundqvist, H. Lundqvist Department of Svedberg Laboratory, Uppsala University, SwedenSearch for more papers by this authorM. Haaparanta, M. Haaparanta Department of Medical Cyclotron Laboratory, University of Turku, FinlandSearch for more papers by this authorO. Solin, O. Solin Department of Medical Cyclotron Laboratory, University of Turku, FinlandSearch for more papers by this authorG. Antoni, G. Antoni Department of Organic Chemistry, Uppsala University, SwedenSearch for more papers by this authorA. D. Gee, A. D. Gee Department of Organic Chemistry, Uppsala University, SwedenSearch for more papers by this authorJ. Ulin, J. Ulin Department of Organic Chemistry, Uppsala University, SwedenSearch for more papers by this authorB. Långström, B. Långström Department of Organic Chemistry, Uppsala University, SwedenSearch for more papers by this author First published: January 1990 https://doi.org/10.1111/j.1600-0404.1990.tb00926.xCitations: 61AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract The kinetics in brain of the dopamine reuptake blocking agent [11C]-(+)-nomifensine and the L-dopa analogue 6-[18F]fluoro-L-dopa were compared in 3 patients with idiopathic Parkinson's disease and age-matched healthy volunteers using positron emission tomography. Regional uptake was analyzed and quantified according to a 3-compartment model. Retention of both tracers in striatal regions of the parkinsonian patients were reduced compared with the healthy volunteers mainly in the putamen, while the caudate nucleus was only mildly affected. The reductions were considerably less than the decrease previously reported postmortem for striatal dopamine content in the basal ganglia of patients with Parkinson's disease. A fairly constant ratio between 6-[18F]fluoro-L-dopa utilization and [11C]-(+)-nomifensine binding in the caudate nucleus and the putamen were found in both groups unrelated to the size of the estimated parameters. This indicates that a limiting factor for the utilization of exogenous levodopa in Parkinson's disease may be a reduced transport capacity for the amino acid into the dopaminergic terminals. References 1 Nahmias C, Garnett SE, Firnau G, Lang A. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 1985: 69: 223– 230. 2 Rutgers AWF, Lakke JPWF, Paans AMJ, Vaalburg W, Korf J. Tracing of dopamine receptors in hemiparkinson with positron emission tomography (PET). J Neurol Sci 1987: 80: 237– 248. 3 Leenders KL, Palmer A, Turton D et al. Dopa uptake and dopamine receptor binding visualized in the human brain: recent developments in Parkinson's disease. New York : Raven Press, 1986: 103– 113. 4 Hägglund J, Aquilonius S-M, Eckernäs S-Å et al. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone. Acta Neurol Scand 1987: 75: 87– 94. 5 Garnett ES, Nahmias C, Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 1984: 11: 174– 179. 6 Tedroff J, Aquilonius S-M, Hartvig P et al. Monoamine reuptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand 1988: 77: 192– 201. 7 Martin WRW, Adam MJ, Bergström M et al. In vivo study of DOPA metabolism in Parkinson's disease. In: S Fahn et al, eds. Recent developments in Parkinson's disease. New York : Raven Press, 1986: 97– 102. 8 Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983: 305: 137– 138. 9 Leenders KL, Palmer AJ, Quinn N et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986: 49: 853– 860. 10 Ulin J, Gee AD, Malmborg P, Tedroff J, Långström B. Synthesis of racemic, (+) and (-)N-[11C]methyl-nornomifensine, a ligand for evaluation of monoamine re-uptake sites by use of positron emission tomography. Appl Radiol Isotope 1989: 40: 171– 176. 11 Aquilonius S-M, Bergström K, Eckernäs S-Å et al. In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. Acta Neurol Scand 1987: 76: 283– 287. 12 Dubocovich ML, Zahniser NR. Binding characteristics of the dopamine uptake inhibitor [3H]nomifensine to striatal membranes. Biochem Pharmacol 1985: 34: 1137– 1144. 13 Scatton B, Dubois A, Dubocovich ML, Zahniser NR, Fage D. Autoradiographic visualization and quantification of dopamine receptors and uptake sites in the rat and human CNS. Life Sci 1985: 36: 815– 822. 14 Schacht U, Leven M. Stereoselective inhibition of synaptosomal catecholamine uptake by nomifensine. Eur J Pharmacol 1984: 98: 275– 277. 15 Leenders KL, Aquilonius S-M, Bergström K et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res 1988: 445: 61– 67. 16 Chirakal R, Firnau G, Garnett ES. High yield synthesis of 6-[18F]fluoro-L-dopa. J Nucl Med 1986: 27: 417– 421. 17 Haaparanta M, Sipilä H, Solin O. Fast HPLC separation of [18F]fluorodopa isomers. Med Appl Cycl IV Ann Univ Turkuensis D 1988: 27: 229– 232. 18 Mintun MA, Raichle ME, Kilbourn MR, Wooten FG, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984: 15: 217– 227. 19 Perlmutter JS, Larson KB, Raichle ME et al. Strategies for in vivo measurements of receptor binding using positron emission tomography. J Cereb Blood Flow Metab 1986: 6: 154– 169. 20 Wong DF, Gjedde A, Wagner HN Jr. Quantification of neuroceptors in the living human brain I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986: 6: 137– 146. 21 Eckernäs S-Å, Aquilonius S-M, Hartvig P et al. Positron emission tomography (PET) in the study of dopamine receptors in the primate brain: evaluation of a kinetic model using 11C-N-methylspiperone. Acta Neurol Scand 1987: 75: 168– 178. 22 Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986: 231: 258– 261. 23 Hartvig P, Eckernäs S-Å, Ekblom B et al. Receptor binding and selectivity of three 11C-labelled dopamine receptor antagonists in the brain of Rhesus monkeys studied with positron emission tomography. Acta Neurol Scand 1988: 77: 314– 321. 24 Sokoloff L, Reivich M, Kennedy C et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977: 28: 897– 916. 25 Lundqvist H, Andersson J, Tedroff J. Quantitative analysis of receptor binding studies with positron emission tomography. EC workshop, Brussels, 1988. Unpublished. 26 Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease; effect of L-dopa therapy. J Pharm Exp Ther 1975: 3: 453– 464. 27 Lloyd K, Hornykiewicz O. Parkinson's disease activity of L-dopa decarboxylase in discrete brain regions. Science 1970: 170: 1212– 1213. 28 Lindberg RLP, Syvälahti EKG. Metabolism of nomifensine after oral and intravenous administration. Clin Pharmacol Ther 1986: 39: 378– 383. 29 Heptner W, Hornke I, Uihlein M. Kinetics and metabolism of nomifensine. J Clin Psychiatry 1984: 45: 21– 25. 30 Costall B, Naylor RJ. Further aspects of nomifensine pharmacology. Br J Clin Pharmacol 1977: 4: 89– 99. 31 Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RSJ. Inhibition of L-dopa uptake into the human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986: 20: 258– 262. 32 Wade L, Katzman R. Rat brain regional uptake and decarboxylation of L-DOPA following carotid injection. Am J Physiol 1975: 228: 352– 359. 33 Firnau G, Garnett ES, Chirakal R, Sudesh S, Nahmias C, Schrobilgen G. [18F]fluoro-L-dopa for the in vivo study of intracerebral dopamine. Int J Radiat Appl Instrum 1986: 37: 669– 675. 34 Chiueh CC, Burns RS, Kopin IJ et al. Determination and visualization of damage to striatal dopaminergic terminals in N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP)-induced parkinsonian monkeys by fluorine-18 labelled 6-fluoro-L-dopa and positron emission tomography. Adv Neurol 1987: 45: 167– 169. 35 Garnett ES, Firnau G, Chan PKH, Sood S, Belbeck W. [18F]fluorodopa, an analogue of dopa, and its use in direct external measurement of storage, degradation, and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 1978: 75: 464– 467. 36 Wade LA, Katzman R. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 1975: 17: 131– 136. 37 Boyes BE, Cumming P, Martin WRW, McGeer EG. Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci 1986: 39: 2243– 2252. 38 Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Metabolites of 6-[18F]fluoro-L-dopa in human blood. J Nucl Med 1988: 29: 363– 369. 39 Mazziotta JC, Phelps ME, Plummer D, Kuhl D. Quantitation in positron emission computed tomography: physical-anatomical effects. J Comput Assist Tomogr 1981: 5 (5): 734– 743. 40 Litton J, Bergström L, Eriksson L, Bohm C, Blomqvist G, Kesselberg M. Performance study of the PC-384 positron camera system for emission tomography of the brain. J Comput Assist Tomogr 1984: 8: 74– 87. 41 Bernheimer H, Birkmeyer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 1973: 20: 415– 455. 42 Firnau G, Sood S, Chirakal R, Garnett ES. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 1987: 48: 1077– 1082. 43 Hira M, Kitamura N, Hashimoto T et al. [3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics. Jpn J Pharmacol 1988: 47: 237– 243. 44 Melamed E, Hefti F, Pettibone DJ et al. Aromatic L-amino acid decarboxylase in rat corpus striatum: implications of action of L-dopa in parkinsonism. Neurology 1981: 31: 651– 655. 45 Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons cover exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980: 8: 558– 563. 46 Nyberg P, Nordberg A, Wester P et al. Dopaminergic deficiency is more pronounced in the putamen than in nucleus caudatus in Parkinson's disease. Neurochem Pathol 1983: 1: 193– 202. Citing Literature Volume81, Issue1January 1990Pages 24-30 ReferencesRelatedInformation
Referência(s)